Quality Improvement Project to Increase Human Papillomavirus Two-Dose Vaccine Series Completion by 13 Years in Pediatric Primary Care Clinics

被引:1
|
作者
Smajlovic, Amina [1 ,2 ,3 ]
Toth, Christina D. [1 ]
机构
[1] Nationwide Childrens Hosp, Ctr Clin Excellence, Columbus, OH USA
[2] Ohio State Univ, Dept Pediat, Div Primary Care Pediat, Coll Med, Columbus, OH USA
[3] 700 Childrens Dr, Columbus, OH 43205 USA
关键词
Human papillomavirus vaccine; 13-years; HPV immunization completion rates; Quality improvement; HPV; Minority; teens; QI; AGED; 13-17; YEARS; UNITED-STATES; HPV; ADOLESCENTS; COVERAGE; COMMUNICATION; PREVALENCE; HESITANCY;
D O I
10.1016/j.jadohealth.2023.01.011
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
ABS T R A C T Purpose: The human papillomavirus (HPV) causes genitourinary and oropharyngeal cancers. HPV vaccine is safe and effective in preventing those diseases; however, vaccine series completion rates remain low in the United States. Our quality improvement (QI) project aimed to increase HPV-vaccination series completion rates to 70% from 2017 to 2020 for the 13-year patient popu-lation in an extensive academic pediatric primary care network that serves predominantly nority and Medicaid-insured children in Columbus, OH. Methods: The outcome measure was the percentage of 13-years Nationwide Children's Hospital Primary Care Network patients who completed the two-dose vaccine series by their birthday. Four QI implemented interventions were utilized. Electronic medical records informed providers when the HPV vaccines are due. We studied monthly data for the network and for individual clinics using statistical process control, displaying data on a control chart. followed two process measures, captured opportunity rate, and the number of HPV vaccines given. Results: We substantially increased HPV-vaccination series completion rates overall in the 13-year teen population from 27% to 65%, and three clinics reached the 70% goal for at least one quarter. Latino children had the highest completion rate of 80% and White children had the lowest completion rate at 64%. Discussion: Our QI project used four measures to improve HPV-vaccination series completion in the 13-year patient population that serves minority and low-income teens predominantly. Further QI studies are needed to improve HPV vaccine completion rates in teens. (c) 2023 Society for Adolescent Health and Medicine. All rights reserved.
引用
收藏
页码:958 / 963
页数:6
相关论文
共 10 条
  • [1] Human Papillomavirus Vaccine Completion by 13: A Quality Improvement Initiative in a Large Primary Care Network
    Huang, Elena
    Filograna, Kathleen
    Lockwood, Katie K.
    Crossette, Jonathan
    Jenssen, Brian P.
    Filograna, K.
    Lockwood, Kk
    Crossette, J.
    [J]. ACADEMIC PEDIATRICS, 2024, 24 (02) : 293 - 301
  • [2] Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older
    Ackerson, Bradley
    Qian, Lei
    Sy, Lina S.
    Bruxvoort, Katia
    Wu, Jun
    Luo, Yi
    Diaz-Decaro, John
    Talarico, Carla
    Tseng, Hung Fu
    [J]. VACCINE, 2021, 39 (06) : 926 - 932
  • [3] A quality improvement education initiative to increase adolescent human papillomavirus (HPV) vaccine completion rates
    Bonville, Cynthia A.
    Domachowske, Joseph B.
    Suryadevara, Manika
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (7-8) : 1570 - 1576
  • [4] HUMAN PAPILLOMAVIRUS VACCINE SERIES COMPLETION RATES AMONG PEDIATRIC, FAMILY MEDICINE, AND GYNECOLOGY CLINICS IN WEST TEXAS
    Thambuswamy, J. T.
    Levent, F.
    Nur, M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 420 - 420
  • [5] GENDER DIFFERENCES IN HUMAN PAPILLOMAVIRUS VACCINE SERIES COMPLETION RATE AMONG CHILDREN AND ADOLESCENTS IN ACADEMIC PEDIATRIC OUTPATIENT CLINICS IN WEST TEXAS
    Williams, B.
    Levent, F.
    Nur, M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (02) : 689 - 689
  • [6] Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study
    Basu, Partha
    Muwonge, Richard
    Bhatla, Neerja
    Nene, Bhagwan M.
    Joshi, Smita
    Esmy, Pulikottil O.
    Poli, Usha Rani Reddy
    Joshi, Geeta
    Verma, Yogesh
    Zomawia, Eric
    Shastri, Surendra S.
    Pimple, Sharmila
    Anantharaman, Devasena
    Prabhu, Priya R.
    Hingmire, Sanjay
    Sauvaget, Catherine
    Lucas, Eric
    Pawlita, Michael
    Gheit, Tarik
    Jayant, Kasturi
    Malvi, Sylla G.
    Siddiqi, Maqsood
    Michel, Angelika
    Butt, Julia
    Sankaran, Subha
    Kannan, Thiraviam Pillai Rameshwari Ammal
    Varghese, Rintu
    Divate, Uma
    Willhauck-Fleckenstein, Martina
    Waterboer, Tim
    Mueller, Martin
    Sehr, Peter
    Vashist, Shachi
    Mishra, Gauravi
    Jadhav, Radhika
    Thorat, Ranjit
    Tommasino, Massimo
    Pillai, M. Radhakrishna
    Sankaranarayanan, Rengaswamy
    [J]. PAPILLOMAVIRUS RESEARCH, 2019, 7 : 75 - 81
  • [7] Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9–14 Years in the EU
    Katherine A. Lyseng-Williamson
    [J]. Pediatric Drugs, 2014, 16 : 247 - 253
  • [8] Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9-14 Years in the EU
    Lyseng-Williamson, Katherine A.
    [J]. PEDIATRIC DRUGS, 2014, 16 (03) : 247 - 253
  • [9] Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
    Madhi, Shabir A.
    Mutsaerts, Eleonora A. M. L.
    Izu, Alane
    Boyce, Welekazi
    Bhikha, Sutika
    Ikulinda, Benit T.
    Jose, Lisa
    Koen, Anthonet
    Nana, Amit J.
    Moultrie, Andrew
    Roalfe, Lucy
    Hunt, Adam
    Goldblatt, David
    Cutland, Clare L.
    Dorfman, Jeffrey R.
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (12): : 1426 - 1436
  • [10] Immunogenicityofa single-dosecompared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial (vol 25, 2020)
    Madhi, S. A.
    Mutsaerts, E. A. M. L.
    Izu, A.
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (11): : E275 - E275